UGT1A1 and colorectal cancer: The UGT1A1 polymorphic status of the patient and the plasma levels of unconjugated bilirubin have emerged as potential biomarkers for the effect of SCO-101 in combination with chemotherapy, and recent data suggest that SCO-101 may lead to renewed sensitivity in chemotherapy-resistant colorectal cancer patients [58].